Within the context of the MEA region's maturing regulatory environment, the expansion of healthcare coverage and regulatory changes aimed at making the New Molecular Entities (NMEs) review process more efficient, registrations have increased in Saudi Arabia, UAE, Tunisia and Egypt, but slowed down in other territories. Results from the second wave of a PhRMA-commisioned IQVIA market access study covering Saudi Arabia (KSA), UAE, Kuwait, Lebanon, Jordan, Egypt, Algeria, Morocco, Tunisia and South Africa (RSA).
Hecho conVisme Infographic Maker
The NMEs included in the report have been registered either with the US FDA or the EU EMA. IQVIA conducted the first wave of the study in 2018.
